ARALEZ PHARMACEUTICALS ARALEZ PHARMACEUTICALS ARALEZ PHARMACEUTICALS ARALEZ PHARMACEUTICALS
  • About
      • About Us
    • History
      • Our Company
      • Our Mission
    • Leadership
      • Board of Directors
      • Management
    • We Care
      • Environmental Commitment
  • Portfolio
      • Portfolio
  • Investors
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Investment Calculator
      • Stock Dividends/Basis
      • Analyst Coverage
    • News Releases
      • News Releases
    • Presentations & Webcasts
      • Upcoming Events
      • Past Events
      • Presentations
    • Financial Information
      • SEC Filings
      • Quarterly Results
      • Annual Reports & Proxies
    • Shareholder Resources
      • Email Alerts
      • FAQ
      • IR Contact Information
      • Information Request
    • Corporate Governance
      • Overview
      • Committee Composition
      • Charters/Policies
      • Sunshine Act
  • News
      • News
    • Aralez Pharmaceuticals
      • Archive News
      • Historical Presentations
    • Pozen
      • Archive News
      • Historical Filings
      • Historical Presentations
    • Tribute Pharmaceuticals
      • Archive News
      • Historical Filings
      • Historical Presentations
  • Careers
      • Careers
    • More Information
      • Working at Aralez
      • Recruiting Agencies
  • Contact Us
      • Contact Us
    • Global Headquarters
      • 7100 West Credit Avenue
        Suite 101
        Mississauga, Ontario L5N 0E4
        905-876-1118
    • Irish Headquarters
      • 56 Fitzwilliam Square
        Dublin 2, Ireland
    • U.S. Headquarters
      • 3 Columbus Circle
        Suite 1710
        New York, NY 10019
ARALEZ PHARMACEUTICALS ARALEZ PHARMACEUTICALS
  • About
    • History
      • Our Mission
    • Leadership
      • Management
  • Portfolio
    • Cardiovascular
      • Bezalip SR
      • Fibricor
      • Viskazide
      • Visken
      • YOSPRALA
    • Pain
      • Cambia
      • Durela
      • Fiorinal
      • FiorinalC
      • NeoVisc
      • Treximet
      • Uracyst
      • Vimovo
      • MT400
    • Other Specialties
      • Balanse
      • Balanse Diaflor
      • Balanse Kids
      • CollatampG
      • Iberogast
      • MoviPrep
      • Mutaflor
      • PegaLAX
      • Proferrin
      • Purfem
      • Resultz
  • Investors
    • Stock Information
  • News
    • Aralez Pharmaceuticals
      • Archive News
      • Historical Presentations
    • Pozen Pharmaceuticals
      • Archive News
      • Historical Filings
      • Historical Presentations
    • Tribute Pharmaceuticals
      • Archive News
      • Historical Filings
      • Historical Presentations
  • Careers
    • External Recruiting Agencies
  • Contact Us
  • family
    Learn More
  • lab
    Learn More About Our Portfolio
  • hands
    Investors
    Get more information on how you can grow with us.
    Investors Information
  • heart
    Cardiovascular
    View Our Portfolio Page in this Therapeutic Category.
    Learn More

About Aralez

The combination of POZEN and Tribute Pharmaceuticals represents an important strategic transformation that created Aralez Pharmaceuticals, a specialty pharmaceutical company with a compelling growth platform.

Our Portfolio

The Aralez portfolio of approved and investigational products is anchored in cardiovascular disease therapies, with a significant pain treatment franchise, and plans for continued development and growth in these and other specialty areas.

For Investors

Aralez is focused on delivering meaningful products to improve patients’ lives while growing shareholder value in short, medium and long-term. Investor information such as press releases, presentations and webcasts can be found in this section.

Cardiovascular Health
   Cardiovascular Health
Pain Management
Pain Management
Other Products
Other Products
Portfolio
Products Portfolio

About Aralez

The combination of POZEN Inc. and Tribute Pharmaceuticals represents an important strategic transformation, creating Aralez Pharmaceuticals, a specialty pharmaceutical company with a compelling growth platform.

RSS Press Releases

  • Aralez To Announce Third Quarter 2016 Results On November 7, 2016
  • Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL®
  • Aralez Announces U.S. Commercial Launch Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers

Site Map

Home
About
Portfolio
Investors
News
Careers
Contact Us

Contact Info

Email: [email protected]
Sign up for news alerts
Legal Notice
Privacy Policy

© 2016 Aralez Pharmaceuticals Inc.
Hosted and managed by Body1